Recombinant Human Transforming Growth Factor, Beta Receptor II (70/80kDa)

• Cat.No.: TGFBR2-1684H

Specification

• Cat. No.: TGFBR2-1684H
• Description: Transforming growth factor beta type II (TGFbeta RII) is a key inhibitor of epithelial cell growth and tumor suppressor gene. It also regulate cell differentiation and has critical regulatory roles in the process of tissue repair and remodeling. TGF beta RII plays an important role as a tumor suppressor in non-small cell lung cancer (NSCLC) carcinogenesis. TGF can be found in many different tissue types, including brain, heart, kidney, liver and testes. Over-expression of TGF can induce renal fibrosis, causing kidney disease, as well as diabetes, and ultimately end-stage renal disease (ESRD). Recent developments have found that, using certain types of protein antagonists against TGFβ receptors, can halt and in some cases reverse the effects of renal fibrosis. Three TGF-β receptor types can be distinguished by their structural and functional properties. Receptor types I and II have similar ligand binding affinities and can only be distinguished from each other by peptide mapping, both receptor types I and II have a high affinity for TGF-β1 and low affinity for TGF-β2. TGF-β receptor type III has a high affinity for both TGF-β1 and -β2.
• Molecular Weight: The predicted molecular weight of Recombinant Human TGF-β sRII is Mr 82 kDa.
• Source: Mammalian cells
• State Of Matter: Lyophilized.
• Purity: >97% by SDS Page and analyzed by silver stain.
• Endotoxin: <1.0 EU/µg as determined by the LAL method.
• Biological Activity: The biological activity of Human TGF-β sRII was determined by its ability to inhibit TGF-β1 activity on a mouse T cell line, HT2. The expected ED50 for this effect is typically 10 - 40 ng/mL in the presence of 1 ng/mL of rhTGF-β1.
• Storage And Stability: This lyophilized protein is stable for six to twelve months when stored desiccated at -20℃ to -70℃. After aseptic reconstitution, this protein may be stored at 2℃ to 8℃ for one month or at -20℃ to -70℃ in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles. See Product Insert for exact lot specific storage instructions.
• Tag: Non

Gene Information

• Gene Name: TGFBR2 transforming growth factor, beta receptor II (70/80kDa) [ Homo sapiens ]
• Synonyms: TGFBR2; transforming growth factor, beta receptor II (70/80kDa); AAT3; FAA3; MFS2; RIIC; LDS1B; LDS2B; TAAD2; TGFR-2; TGFbeta-RII; TGF-beta type II receptor; TGF-beta receptor type IIB; transforming growth factor beta receptor type IIC; EC 2.7.11.30
• Gene ID: 7048
• mRNA Refseq: NM_001024847
• Protein Refseq: NP_001020018
• MIM: 190182
• UniProt ID: P37173
• Chromosome Location: 3p22
• Pathway: Adherens junction; Chronic myeloid leukemia; Colorectal cancer; Cytokine-cytokine receptor interaction; Endocytosis; MAPK signaling pathway; Pancreatic cancer; TGF-beta signaling pathway; Signaling by TGF beta
• Function: ATP binding; SMAD binding; glycosaminoglycan binding; magnesium ion binding; manganese ion binding; protein heterodimerization activity; receptor activity; transferase activity; transforming growth factor beta binding; transforming growth factor beta receptor activity, type II; type I transforming growth factor beta receptor binding

Reviews

04/14/2023

TGFBR2 protein's remarkable performance in ELISA and protein electron microscopy structure analysis positions it as a valuable tool in various fields, including cardiovascular research, developmental biology, and molecular medicine.

12/13/2022

TGFBR2 protein's utility extends to protein electron microscopy structure analysis, where it plays a crucial role in investigating the detailed architecture and conformational changes of proteins.

06/25/2021

TGFBR2 protein is highly recommended for use in various research applications, including ELISA and protein electron microscopy structure analysis.

Q&As

How is TGFBR2 linked to autoimmune diseases?

Dysregulation of TGF-beta signaling, including TGFBR2, has been associated with autoimmune diseases. Understanding these pathways may provide insights into developing targeted therapies.

Are there clinical trials targeting TGFBR2?

Yes, there are ongoing clinical trials exploring the modulation of TGFBR2 for various conditions, including cancer and fibrotic diseases.

How does TGFBR2 affect cardiovascular health?

TGFBR2 is involved in cardiovascular development and homeostasis. Dysregulation can contribute to conditions like aortic aneurysms and other cardiovascular diseases.

Is TGFBR2 involved in neurological disorders?

Some studies suggest a potential link between TGFBR2 and neurological disorders. Further research is ongoing to understand its role in conditions like Alzheimer's and Parkinson's disease.

Can TGFBR2 be a therapeutic target for fibrotic diseases?

Yes, TGFBR2 is implicated in fibrosis, and targeting it may offer therapeutic options for diseases characterized by excessive tissue scarring.